Home>>Proteins>> Hormones>> Peptide Hormones>>Glucose-dependent Insulinotropic Polypeptide (1-39) (porcine) (trifluoroacetate salt)

Glucose-dependent Insulinotropic Polypeptide (1-39) (porcine) (trifluoroacetate salt) (Synonyms: Gastric Inhibitory Peptide (1-39),GIP (1-39))

Catalog No.GC91868

Glucose-dependent Insulinotropic Polypeptide (GIP) (1-39) is an endogenous 39-amino acid peptide hormone that induces insulin secretion.

Products are for research use only. Not for human use. We do not sell to patients.

Glucose-dependent Insulinotropic Polypeptide (1-39) (porcine) (trifluoroacetate salt) Chemical Structure

Cas No.: N/A

Size Price Stock Qty
1 mg
$85.00
In stock
5 mg
$337.00
In stock
10 mg
$549.00
In stock
25 mg
$1,054.00
In stock

Tel:(909) 407-4943 Email: sales@glpbio.com


Customer Reviews

Based on customer reviews.

  • GlpBio Citations

    GlpBio Citations
  • Bioactive Compounds Premium Provider

    Bioactive Compounds Premium Provider

Sample solution is provided at 25 µL, 10mM.

Description Chemical Properties Product Documents

Glucose-dependent Insulinotropic Polypeptide (GIP) (1-39) is an endogenous 39-amino acid peptide hormone that induces insulin secretion.[1] It has been found in the upper intestines of pigs. GIP (1-39) (100 nM) enhances glucose-induced increases in insulin release in primary rat pancreatic β-cells to a greater extent than GIP (1-42).

References:
[1].Xie, L., Lu, J., Östenson, C.-G., et al.GIP1-39, a novel insulinotropic peptide form and aspects on its mechanism of actionRegul. Pept.121(1-3)107-112(2004).

Reviews

Review for Glucose-dependent Insulinotropic Polypeptide (1-39) (porcine) (trifluoroacetate salt)

Average Rating: 5 ★★★★★ (Based on Reviews and 30 reference(s) in Google Scholar.)

5 Star
100%
4 Star
0%
3 Star
0%
2 Star
0%
1 Star
0%
Review for Glucose-dependent Insulinotropic Polypeptide (1-39) (porcine) (trifluoroacetate salt)

GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.

Required fields are marked with *

You may receive emails regarding this submission. Any emails will include the ability to opt-out of future communications.